Expert Insights on Complex Clinical Cases of Edema

Slides:



Advertisements
Similar presentations
Evaluation and Management of Acute Decompensated Heart Failure
Advertisements

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
EVIDENCE IN THE ED AMOS SHEMESH, MD, PGY-III MARCH 2014 LMNOP in ADHF: Should Lasix Stay in the Acronym?
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Purpose To determine whether metoprolol controlled/extended release
Pam Charity, MD Cathryn Caton, MD, MS.  Define pneumonia  Review criteria for diagnosis  Review criteria for admission  Review treatment options.
analysis from the SHIFT study
Inpatient Management of Heart Failure Mini-Lecture.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
Patient education tools are key to the follow- up of chronic heart failure patients.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Digoxin ‘it has a power over the motion of the heart to a degree yet unobserved in any other medicine…’ Withering, 1775.
CARRESS Cardiorenal Rescue Study in Acute Decompensated Heart Failure Duke Heart Failure Research Pager:
DOSE-AHF Diuretic Optimization Strategies Evaluation in Acute Heart Failure Duke Heart Failure Research Pager:
DRUG TREATMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC RENAL DISEASE Presented by Ri.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Metformin Use in Chronic Kidney Disease
Exhaled Acetone as a New Biomarker of Heart Failure Severity
CLINICAL DILEMMAS IN HEART FAILURE:
Emerging Concepts in Heart Failure
Windhi Dwijanarko RSU DADI KELUARGA, PURWOKERTO
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.
Acute Heart Failure.
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
At The Cutting Edge of Developments in the Management of Hyperkalemia
ACUTE DECOMPENSATD HEART FAILURE AND CARDIORENAL SYNDROME
Biomarkers in Heart Failure
The three components of patient self-care
PCP Perspectives Clinical Considerations in Hyperkalemia
Neurostimulation for the Management of Medication-Resistant Epilepsy
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
Resistant Hypertension
Addressing Iron Deficiency in Chronic HF
Heart Failure Management Coordinated Care Approaches
Expert Perspectives on Hyperkalemia for the Specialist
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
Efficacy and Safety of Edoxaban in Patients With AF and HF
Biomarker-Guided HF Therapy: Is It Cost-Effective?
At The Cutting Edge of Developments in the Management of Hyperkalemia
Using Heart Rate as a Biomarker in Clinical Practice.
acute, chronic, or acute on chronic.
Case #1 Case #1 (cont) Case #1 (cont)
Updates in Heart Failure:
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Shifting Currents in Hyperkalemia Management 2015 in Review
Shifting Currents in Hyperkalemia Management 2015 in Review
Maintenance Therapy in Advanced Ovarian Cancer
Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018
CAD and HF Often Coexist
Diuretics By S.Bohlooli, PhD.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Iron Deficiency in Heart Failure
What is the relative risk reduction of ACEi’s/beta blockers for HFrEF?
Live on PAH: Breathing Life Into Patients With PAH
Assessing the Burden of Hyperkalemia
AMD Therapy: Where Are We Now and Where Are We Going?
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Assessing the Burden of Hyperkalemia
Uptitration of Medications in HF: Start Low but Aim High and Stay High
In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?
Pro-inflammatory biomarkers in decompensated and stable HFpEF patients
Cohort and Community Surveillance Components
My PAH Patient.
Key Data on Improving Outcomes in HF Patients
Understanding the Role of Disability in MS Management
Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.
Presentation transcript:

Expert Insights on Complex Clinical Cases of Edema

Objectives

Case 1: Mr. S

Initial Management Steps

Early Data

Effect of Diuretic Dosing on Mortality in Acute HF

Loop Diuretics in Patients With ADHF

Treatment Plan for Mr. S

Impact of Worsening Renal Function

Mr. S: Renal Characteristics

Thiazide + Loop

Case 2: Mrs. M

Physical Exam

Collect Patient Data

Patient X-Ray

Management Approach for Mrs. M

1-Week Follow Up

Mrs. M’s Long-Range Management

Efficacy of Diuretics for Management of Chronic Heart Failure

Mrs. M 1 Year Later

Mechanisms of Diuretic Resistance

Diuretic Resistance

Mrs. M After Medication Adjustment

Mrs. M After Medication Adjustment (cont)